Cargando…

Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia

Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by ectopic production of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMTs). Acting on renal tubule cells, excess FGF23 decreases phosphate reabsorption and 1,25‐dihydroxy‐vitamin D (1,25D) productio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartley, Iris R., Roszko, Kelly L., Li, Xiaobai, Pozo, Karen, Streit, Jamie, del Rivero, Jaydira, Magone, M. Teresa, Smith, Michaele R., Vold, Roo, Dambkowski, Carl L., Collins, Michael T., Gafni, Rachel I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382865/ https://www.ncbi.nlm.nih.gov/pubmed/35991529 http://dx.doi.org/10.1002/jbm4.10661

Ejemplares similares

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

Scintigraphic Findings in FGF23-related Hypophosphatemic Osteomalacia
por: Fujita, Naoya, et al.
Publicado: (2023)

Phosphate and FGF-23
por: Jüppner, Harald
Publicado: (2011)

Selective blood sampling for FGF-23 in tumor-induced osteomalacia
por: Schober, Hans-Christof, et al.
Publicado: (2017)

MON-502 It's Not Always Osteoporosis: FGF-23 Induced Osteomalacia
por: Bello Segura, Manuel, et al.
Publicado: (2019)

Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption
por: Hidaka, Naoko, et al.
Publicado: (2021)

Tumor-Induced Osteomalacia With Normal Fibroblast Growth Factor-23 (FGF23) and Idiopathic Hypercalciuria
por: Velazquez-Navarro, Jassel A, et al.
Publicado: (2022)

A Normal FGF23 Does Not Preclude Tumor‐Induced Osteomalacia
por: Nandam, Neeharika, et al.
Publicado: (2020)

Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia
por: Fukumoto, Seiji
Publicado: (2014)

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
por: Amarnani, Raj, et al.
Publicado: (2020)

Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer
por: Abramson, Matthew, et al.
Publicado: (2021)

Diagnostic Dilemma of Elevated FGF23 in a Patient With Osteomalacia: A Case Report
por: Bulut, Aysegul, et al.
Publicado: (2021)

Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism
por: Saito, Tasuku, et al.
Publicado: (2009)

FGF23 and Phosphate–Cardiovascular Toxins in CKD
por: Vogt, Isabel, et al.
Publicado: (2019)

Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis
por: Westerberg, Per-Anton, et al.
Publicado: (2012)

SAT-385 A Normal FGF23 Does Not Preclude Tumor Induced Osteomalacia (TIO)
por: Nandam, Neeharika, et al.
Publicado: (2020)

Treating ‘osteoporosis’: a near miss in an unusual case of FGF-23-mediated hypophosphataemic osteomalacia
por: Lin, Mike, et al.
Publicado: (2022)

Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO)
por: Kinoshita, Yuka, et al.
Publicado: (2018)

Molecular interactions of FGF23 and PTH in phosphate regulation
por: Lanske, Beate, et al.
Publicado: (2014)

Multiple Looser zones of osteomalacia in Byler disease with associated vitamin D deficiency, phosphaturia, and elevated FGF23
por: Tarazi, M., et al.
Publicado: (2015)

Phosphate control in reducing FGF23 levels in hemodialysis patients
por: Rodelo-Haad, Cristian, et al.
Publicado: (2018)

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
por: Lassman, Andrew B., et al.
Publicado: (2022)

A Case of Acute Prosthesis Migration after Femoral Head Replacement due to Osteomalacia by FGF23-Induced Tumor
por: Hayashi, Shinya, et al.
Publicado: (2012)

Dramatic mitigation of bone pain after phosphorus replacement therapy in a subject with FGF23-related hypophosphatemic osteomalacia
por: Tatsumi, Fuminori, et al.
Publicado: (2016)

OR23-03 Sustained Normalization Of Mineral Homeostasis In Autosomal Dominant Hypocalcemia Type 1: Results From A Phase 2 Study Over 18 Months Of Encaleret (CLTX-305) Treatment (NCT04581629)
por: Ilana Gafni, Rachel, et al.
Publicado: (2023)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia
por: Demuynck, Benoit, et al.
Publicado: (2020)

Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

FGF23 and inflammation
por: Sharaf El Din, Usama A A, et al.
Publicado: (2017)

Genetic Evidence of Serum Phosphate-Independent Functions of FGF-23 on Bone
por: Sitara, Despina, et al.
Publicado: (2008)

FGF-23: More Than a Regulator of Renal Phosphate Handling?
por: Jüppner, Harald, et al.
Publicado: (2010)

PMON30 Low-dose Infigratinib, an Oral Selective Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor, Demonstrates Activity in a Preclinical Model of Hypochondroplasia
por: Dambkowski, Carl, et al.
Publicado: (2022)

Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin
por: Hautmann, Anke H., et al.
Publicado: (2014)

Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome
por: Kumar, S., et al.
Publicado: (2020)

Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants
por: Enlund-Cerullo, Maria, et al.
Publicado: (2023)

Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients
por: Bech, Anneke P., et al.
Publicado: (2015)

Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium
por: McKenna, Malachi J, et al.
Publicado: (2020)

Tumor-induced osteomalacia
por: Florenzano, Pablo, et al.
Publicado: (2017)

A Cross‐Sectional Cohort Study of the Effects of FGF23 Deficiency and Hyperphosphatemia on Dental Structures in Hyperphosphatemic Familial Tumoral Calcinosis
por: Lee, Alisa E, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lepes9s0j1kiil4q3r8fd9mcuj